Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 26, 2022

Axatilimab for Refractory Chronic Graft-vs-Host Disease After Failure of at Least Two Prior Systemic Therapies

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
J. Clin. Oncol 2022 Dec 02;[EPub Ahead of Print], CL Kitko, M Arora, Z DeFilipp, MA Zaid, A Di Stasi, V Radojcic, CB Betts, LM Coussens, ML Meyers, H Qamoos, P Ordentlich, V Kumar, C Quaranto, A Schmitt, Y Gu, BR Blazar, TP Wang, A Salhotra, I Pusic, M Jagasia, SJ Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading